| Document |
Document Title |
|
WO/2022/093079A1 |
The proposed invention relates to nuclear medicine, more particularly to developing a potentially osteotropic therapeutic radiopharmaceutical preparation comprising, as an active ingredient, a complex compound having the following struct...
|
|
WO/2022/092649A1 |
The present invention relates to a composition for enhancing tumor penetration of an anticancer drug, comprising losartan as an active ingredient, and a use thereof. In the composition, losartan decomposes collagen and hyaluronic acid, w...
|
|
WO/2022/093793A1 |
The disclosure relates to nanoparticle drug conjugates (NDC) that comprise ultrasmall nanoparticles, folate receptor (FR) targeting ligands, and linker-drug conjugates, and methods of making and using them to treat cancer.
|
|
WO/2022/092215A1 |
The present invention pertains to an agent for detecting an interaction between tissues and organs, the agent containing a compound represented by general formula (1-0) as an active ingredient. [In general formula (1-0), R represents -O(...
|
|
WO/2022/093800A2 |
The disclosure relates to carrier particle-drug conjugates, including nanoparticle drug conjugates (NDC), that can be used in the delivery of a drug to a biological target (e.g., for targeted delivery of a cytotoxic drug to a cancer cell...
|
|
WO/2022/093845A1 |
Disclosed are systems and methods for retrieving, for a patient with a medical condition, a structured dataset and an unstructured dataset, the structured dataset comprising demographic and clinical data, and the unstructured dataset com...
|
|
WO/2022/092411A1 |
The radioactive liposome nanoparticles for macrophage tracing, derived via the present invention, are considered to be very usefully employed in the diagnosis of a tumor or brain inflammation by quantifying, using PET, activated macropha...
|
|
WO/2022/092887A1 |
The present invention relates to a host cell expressing monomeric streptavidin. The host cell according to the present invention expresses streptavidin in the body, such that it is possible to visualize and monitor, in real time, the dis...
|
|
WO/2022/087416A1 |
Provided are compositions and methods for treating cancers and precancerous proliferative disorders in a mammalian subject that involve the combination use of a radiotherapeutic agent, such as a radiolabeled CD33, DR5, 5T4, HER2, or HER3...
|
|
WO/2022/085571A1 |
A method for producing a radioactive zirconium complex according to the present invention comprises a step for reacting a radioactive zirconium ion, a ligand compound comprising DOTA or a DOTA derivative and an additive such as hydroxybe...
|
|
WO/2022/087174A1 |
The present invention provides methods and compositions for intranasally (IN) treating nervous system disorders such as cognitive, social, or behavioral disabilities, and neurodevelopmental disorders, More specifically, the present inven...
|
|
WO/2022/082312A1 |
The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4...
|
|
WO/2022/077051A1 |
There is provided a method of manufacturing silica microspheres includes the steps of mixing acid and water to form a mixture; adding a silicon alkoxide to the mixture so as to precipitate microspheres; allowing the microspheres to settl...
|
|
WO/2022/077068A1 |
The invention relates to compounds according to Formula (I) wherein A is –As(OH)2 or an arsenoxide equivalent group; each of R1, R2, R3 and R4 is independently selected from H, X, OH, NH2, CO, SCN, -CH2NH, -NHCOCH3, -NHCOCH2X or NO, an...
|
|
WO/2022/080481A1 |
A problem addressed by the present invention is to provide complexes having greater stability than in the past without harming drug efficacy. The complexes of the present invention are complexes of a chelating agent and an anti-HER2 anti...
|
|
WO/2022/081791A1 |
The present disclosure provides processes for the preparation of alpha emitting radiopharmaceutical compositions, in particular DOTATATE complexes of alpha emitting radionuclides, as well as use of such prepared compositions in the treat...
|
|
WO/2022/077923A1 |
The present invention relates to the technical field of radiopharmaceutical chemistry and clinical nuclear medicine, in particular to a benzene ring-containing glucose derivative and an application thereof. The benzene ring-containing gl...
|
|
WO/2022/075950A1 |
The invention relates to a pharmaceutical composition comprising at least one of the calcium isotopes 42Ca, 43Ca, 44Ca, and 46Ca and the anticancer effect of this pharmaceutical composition.
|
|
WO/2022/076741A1 |
Compounds derived from celecoxib and valdecoxib, and methods of use thereof, are disclosed. The compounds are useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of p...
|
|
WO/2022/076523A1 |
The present disclosure reports a C-C chemokine type 2 receptor (CCR2) targeting mediated nanoimmunotherapy to treat cancer, such as pancreatic ductal adenocarcinoma (PDAC). Also disclosed herein is the use of a biodegradable copper nanoc...
|
|
WO/2022/074621A1 |
Described herein are synthetic monoclonal antibodies, built on a human IgG framework, e.g., Trastuzumab, that bind to the spike protein of SARS-CoV-2 (the causative agent of COVID-19), compete for ACE2 binding, and potently inhibit SARS-...
|
|
WO/2022/075713A1 |
The present invention provides a novel protein specifically binding to calreticulin and having the scaffold of human fibronectin domain III and a use thereof, wherein the protein can be used for diagnosing cell damage in an early stage t...
|
|
WO/2022/072293A2 |
The present application relates to methods of treating a subject for cancer. The method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent ...
|
|
WO/2022/069419A1 |
The present invention is in the field of Intelligent Drug Delivery. Targeted medicines have been developed thereto, using a Targeted Mediated Drug Delivery-technology. This technology leads drugs selectively and specifically into disease...
|
|
WO/2022/073003A1 |
The present application provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Y, R1, R2, R3 and R4 are described herein. The methods of using these compounds to inhibit tetramerization of PF4 and to tr...
|
|
WO/2022/072292A1 |
The present application relates to methods of treating and imaging cancer. The methods involve providing a first agent comprising a first targeting component coupled to a cancer therapeutic component or an imaging component and providing...
|
|
WO/2022/061409A1 |
A post unit for holding one end of a carbon crucible utilised in the creation of a carbon encapsulated substance such as Technetium for use in medical imaging and treatment, the post unit including: a detachable contact unit including a ...
|
|
WO/2022/066650A1 |
The present disclosure provides compounds, complexes, compositions, and methods for the detection of cancer. Specifically, the compounds, complexes, compositions of the present technology include pH (low) insertion peptides. Also disclos...
|
|
WO/2022/063850A1 |
The invention relates to a conjugate or a pharmaceutically acceptable salt thereof, the conjugate being of formula: C-L-A, wherein C is a chelator, L is a linker covalently bound to the chelator and A is a Gastrin-releasing peptide recep...
|
|
WO/2022/064812A1 |
The present invention is a method for evaporating and concentrating a radioactive metal nuclide, the method comprising: a first evaporating and concentrating step for heating a radioactive solution obtained by dissolving a radioactive me...
|
|
WO/2022/058338A1 |
The present invention related to a combination of radium-224 (224Ra) and/or progeny of 224Ra, and a DNA repair inhibitor for use in the treatment of cancer. The DNA repair inhibitor can for example be a poly (ADP-ribose) polymerase inhib...
|
|
WO/2022/058337A1 |
The present disclosure relates to a particle comprising a degradable compound, a radionuclide, and a phosphorus containing additive. Phosphorus containing additives, such as phosphonates, have the unique ability to control the size of pa...
|
|
WO/2022/055842A1 |
Provided are methods for treating acute myeloid leukemia that include administering a regimen of venetoclax and lintuzumab-Ac225, in which (a) the regimen includes a plurality of cycles, each cycle lasting from 28 to 60 days, (b) the reg...
|
|
WO/2022/054755A1 |
The present invention relates to providing a new method for easily detecting tumor cells in tissue from a living body. The present invention includes a fluorescent dye containing a compound that exhibits solvatochromism for detecting tum...
|
|
WO/2022/053651A2 |
The present invention relates to the field of antibody fragments, which specifically binds an epitope of human and/or murine FAP and which may be linked to an entity such as a moiety. The antibody fragment and the compound formed may be ...
|
|
WO/2022/054062A1 |
Described herein are synthetic cyclic peptide mimetic s comprising alternating D-amino acids and L-amino acids and amino acid derivatives, such as aza-amino acids and azasulfuryl- amino acids. Optionally, the cyclic peptide mimetic s may...
|
|
WO/2022/050233A1 |
The purpose of the present invention is to provide a cytochrome P450 light emission system which can easily be made to emit light without the need for excitation light; this purpose is met by a light emitting system characterized by cont...
|
|
WO/2022/049523A1 |
The disclosure provides methods comprising administering a therapeutic agent to a plurality of individuals having prostate cancer; performing prostate-specific membrane antigen-positron emission tomography (PSMA-PET) on the individuals a...
|
|
WO/2022/043556A1 |
The present disclosure relates to a pharmaceutical composition of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is a...
|
|
WO/2022/041803A1 |
A visualized radioactive carbon microsphere suspension, and a preparation method and application thereof, relating to the technical field of medicines. Every 1 ml of the visualized radioactive carbon microsphere suspension comprises: 10-...
|
|
WO/2022/043558A1 |
The present invention relates to combinations for use and methods of treating cancers that express prostate specific membrane antigen (PSMA). In particular, the invention provides novel therapies based on the combination of a PSMA therap...
|
|
WO/2022/047417A1 |
The present disclosure provides methods and compositions that include a polynucleotide that includes nucleic acids that encode an anti-idiotype polypeptide, as well as polypeptides that are encoded by the same, and cells that include and...
|
|
WO/2022/042569A1 |
Disclosed are oxygen-containing particles, a manufacturing method therefor, and a use thereof. The oxygen-containing particles comprise a carrier that is safe for the human body and has a large number of micropores or pores distributed o...
|
|
WO/2022/043557A1 |
The present invention relates to combinations for use and methods of treating cancers that express prostate specific membrane antigen (PSMA). In particular, the invention provides novel therapies based on the combination of a PSMA therap...
|
|
WO/2022/045247A1 |
Provided are: a higher-performance bispecific antibody that specifically binds to a mutant calreticulin protein; and a pharmaceutical composition that contains said antibody. Provided is a bispecific antibody having: a first domain tha...
|
|
WO/2022/041804A1 |
A carbon microbead loaded with metal nuclide, a preparation method, and an application. The method comprises: reacting metal ions with organic micro molecules in an aqueous solution to obtain a complex; adsorbing the complex by using car...
|
|
WO/2022/045093A1 |
The present invention relates to a compound represented by formula (I) or (II), a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable salt.
|
|
WO/2022/045748A1 |
The present invention relates to a method for preparing a carbon-13-containing graphene quantum dot available as an MRI contrast medium, a carbon-13-containg graphene quantum dot prepared by the method, and an MRI contrast medium includi...
|
|
WO/2022/041802A1 |
Disclosed is a zirconium carbon microsphere suspension, belonging to the technical field of positron emission computed tomography (PET) developers. Per 1 ml of zirconium [89Zr] carbon microsphere suspension includes: 0.5-200 mg of carbon...
|
|
WO/2022/037262A1 |
Disclosed are a metal nanoparticle containing a radionuclide, a nanomaterial containing the nanoparticle, and a preparation method therefor and the use thereof in the preparation of a targeted drug. A radionuclide is doped in the metal n...
|
